Matching patients with the ever-expanding range of TAVI devices

Nature Reviews Cardiology

Volumn 14, Issue 10, 2017, Pages 615-626

  Jones, Brandon M ^a   Krishnaswamy, Amar ^a   Tuzcu, E Murat ^b   Mick, Stephanie ^a   Jaber, Wael A ^a   Svensson, Lars G ^a   Kapadia, Samir R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HEART AND VASCULAR INSTITUTE   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

AORTIC REGURGITATION; AORTIC VALVE STENOSIS; CORONARY ARTERY OBSTRUCTION; DEVICE SAFETY; HEALTH CARE COST; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HIGH RISK PATIENT; HUMAN; INDIVIDUALIZATION; INTERMEDIATE RISK PATIENT; LOW RISK POPULATION; MEDICAL DECISION MAKING; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTHETIC VALVE DYSFUNCTION; REVIEW; RISK ASSESSMENT; SURGICAL RISK; TECHNOLOGY; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT CONTRAINDICATION; VASCULAR ACCESS;

EID: 85032672379     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2017.82     Document Type: Review

References (64)

1. Freeman, R. V. & Otto, C. M. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111, 3316-3326 (2005).
2. Nishimura, R. A. et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 63, e57-e185 (2014).
3. Ross, J. Jr & Braunwald, E. Aortic stenosis. Circulation 38, 61-67 (1968).
4. Iung, B. et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery Eur. Heart J. 26, 2714-2720 (2005).
5. O'Neill, W. W. Predictors of long-term survival after percutaneous aortic valvuloplasty: report of the Mansfield Scientific Balloon Aortic Valvuloplasty Registry. J. Am. Coll. Cardiol. 17, 193-198 (1991).
6. Kapadia, S. et al. Outcomes of inoperable symptomatic aortic stenosis patients not undergoing aortic valve replacement: insight into the impact of balloon aortic valvuloplasty from the PARTNER trial (Placement of AoRtic TraNscathetER Valve trial). JACC Cardiovasc. Interv. 8, 324-333 (2015).
7. Cribier, A. et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106, 3006-3008 (2002).
8. Leon, M. B. et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 363, 1597-1607 (2010).
9. Kapadia, S. R. et al. 5year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (partner 1): A randomised controlled trial. Lancet 385, 2485-2491 (2015).
10. Popma, J. J. et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J. Am. Coll. Cardiol. 63, 1972-1981 (2014).
11. Smith, C. R. et al. Transcatheter versus surgical aorticvalve replacement in high-risk patients. N. Engl. J. Med. 364, 2187-2198 (2011).
12. Mack, M. J. et al. 5year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (partner 1): A randomised controlled trial. Lancet 385, 2477-2484 (2015).
13. Adams, D. H. et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N. Engl. J. Med. 370, 1790-1798 (2014).
14. Reardon, M. J. et al. 2year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J. Am. Coll. Cardiol. 66, 113-121 (2015).
15. Tamburino, C. et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 123, 299-308 (2011).
16. Athappan, G. et al. Predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. J. Am. Coll. Cardiol. 61, 1585-1595 (2013).
17. Kapadia, S. R. et al. Cerebral embolic protection during transcatheter aortic valve replacement. J. Am. Coll. Cardiol. 69, 367-377 (2017).
18. Giustino, G., Sorrentino, S., Mehran, R., Faggioni, M. & Dangas, G. Cerebral embolic protection during TAVR: A clinical event meta-analysis. J. Am. Coll. Cardiol. 69, 465-466 (2017).
19. Reynolds, M. R. et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRtic TraNscathetER Valve) trial (Cohort A). J. Am. Coll. Cardiol. 60, 548-558 (2012).
20. Reynolds, M. R. et al. Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). J. Am. Coll. Cardiol. 60, 2683-2692 (2012).
21. Piazza, N. et al. 3center comparison of 1year mortality outcomes between transcatheter aortic valve implantation and surgical aortic valve replacement on the basis of propensity score matching among intermediate-risk surgical patients. JACC Cardiovasc. Interv. 6, 443-451 (2013).
22. Latib, A. et al. Transcatheter versus surgical aortic valve replacement in intermediate-surgical-risk patients with aortic stenosis: A propensity score-matched case-control study. Am. Heart J. 164, 910-917 (2012).
23. Tamburino, C. et al. 1year outcomes after transfemoral transcatheter or surgical aortic valve replacement: results from the Italian OBSERVANT study. J. Am. Coll. Cardiol. 66, 804-812 (2015).
24. Schymik, G. et al. A comparison of transcatheter aortic valve implantation and surgical aortic valve replacement in 1,141 patients with severe symptomatic aortic stenosis and less than high risk. Catheter Cardiovasc. Interv. 86, 738-744 (2015).
25. Muneretto, C. et al. Treating the patients in the 'greyzone' with aortic valve disease: A comparison among conventional surgery, sutureless valves and transcatheter aortic valve replacement. Interact. Cardiovasc. Thorac. Surg. 20, 90-95 (2015).
26. Leon, M. B. et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N. Engl. J. Med. 374, 1609-1620 (2016).
27. Thourani, V. H. et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: A propensity score analysis. Lancet 387, 2218-2225 (2016).
28. Nishimura, R. A. et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J. Am. Coll. Cardiol. http://dx.doi.org/10.1161/ CIR.0000000000000503 (2017).
29. Reardon, M. J. et al. Surgical or transcatheter aorticvalve replacement in intermediate-risk patients. N. Engl. J. Med. 376, 1321-1331 (2017).
30. Thyregod, H. G. et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1year results from the all-comers notion randomized clinical trial. J. Am. Coll. Cardiol. 65, 2184-2194 (2015).
31. Rosato, S. et al. Transcatheter aortic valve implantation compared with surgical aortic valve replacement in low-risk patients. Circ. Cardiovasc. Interv. 9, e003326 (2016).
32. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02675114 (2017).
33. Nombela-Franco, L. et al. Significant mitral regurgitation left untreated at the time of aortic valve replacement: A comprehensive review of a frequent entity in the transcatheter aortic valve replacement era. J. Am. Coll. Cardiol. 63, 2643-2658 (2014).
34. Unger, P., Clavel, M. A., Lindman, B. R., Mathieu, P. & Pibarot, P. Pathophysiology and management of multivalvular disease. Nat. Rev. Cardiol. 13, 429-440 (2016).
35. Danson, E. et al. Assessment, treatment, and prognostic implications of CAD in patients undergoing TAVI. Nat. Rev. Cardiol. 13, 276-285 (2016).
36. Pasic, M., Unbehaun, A., Buz, S., Drews, T. & Hetzer, R. Annular rupture during transcatheter aortic valve replacement: classification, pathophysiology, diagnostics, treatment approaches, and prevention. JACC Cardiovasc. Interv. 8, 1-9 (2015).
37. Khatri, P. J. et al. Adverse effects associated with transcatheter aortic valve implantation: A meta-analysis of contemporary studies. Ann. Intern. Med. 158, 35-46 (2013).
38. Zhao, Z. G., Jilaihawi, H., Feng, Y. & Chen, M. Transcatheter aortic valve implantation in bicuspid anatomy. Nat. Rev. Cardiol. 12, 123-128 (2015).
39. Agarwal, S. et al. Transcatheter aortic valve replacement: current perspectives and future implications. Heart 101, 169-177 (2015).
40. Gilard, M. et al. Late outcomes of transcatheter aortic valve replacement in high-risk patients: The France2 registry. J. Am. Coll. Cardiol. 68, 1637-1647 (2016).
41. Mack, M. J. et al. Outcomes following transcatheter aortic valve replacement in the united states. JAMA 310, 2069-2077 (2013).
42. Schymik, G. et al. Long-term results of transapical versus transfemoral tavi in a real world population of 1000 patients with severe symptomatic aortic stenosis. Circ. Cardiovasc. Interv. 8, e000761 (2015).
43. Blackstone, E. H. et al. Propensity-matched comparisons of clinical outcomes after transapical or transfemoral transcatheter aortic valve replacement: A placement of aortic transcatheter valves (PARTNER)-I trial substudy. Circulation 131, 1989-2000 (2015).
44. Zhao, A., Minhui, H., Li, X. & Zhiyun, X. A meta-analysis of transfemoral versus transapical transcatheter aortic valve implantation on 30day and 1year outcomes. Heart Surg. Forum 18, E161-E166 (2015).
45. Patel, J. S. et al. Access options for transcatheter aortic valve replacement in patients with unfavorable aortoiliofemoral anatomy. Curr. Cardiol. Rep. 18, 110 (2016).
46. Cohen, M. G. et al. Transseptal antegrade transcatheter aortic valve replacement for patients with no other access approach-a contemporary experience. Catheter Cardiovasc. Interv. 82, 987-993 (2013).
47. Greenbaum, A. B. et al. Caval-aortic access to allow transcatheter aortic valve replacement in otherwise ineligible patients: initial human experience. J. Am. Coll. Cardiol. 63, 2795-2804 (2014).
48. Mylotte, D. et al. Transcarotid transcatheter aortic valve replacement: feasibility and safety. JACC Cardiovasc. Interv. 9, 472-480 (2016).
49. Gaia, D. F. et al. New braile inovare transcatheter aortic prosthesis: clinical results and followup. EuroIntervention 11, 682-689 (2015).
50. Ribeiro, H. B. et al. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J. Am. Coll. Cardiol. 62, 1552-1562 (2013).
51. Blumenstein, J. et al. Challenges of coronary angiography and intervention in patients previously treated by tavi. Clin. Res. Cardiol. 104, 632-639 (2015).
52. Garcia, E. et al. Transcatheter aortic valve implantation in patients with a mechanical mitral valve [Spanish]. Rev. Esp. Cardiol. 64, 1052-1055 (2011).
53. Mahadevia, R. et al. Bicuspid aortic cusp fusion morphology alters aortic three-dimensional outflow patterns, wall shear stress, and expression of aortopathy. Circulation 129, 673-682 (2014).
54. Mylotte, D. et al. Transcatheter aortic valve replacement in bicuspid aortic valve disease. J. Am. Coll. Cardiol. 64, 2330-2339 (2014).
55. Yoon, S. H. et al. Transcatheter aortic valve replacement with early-and new-generation devices in bicuspid aortic valve stenosis. J. Am. Coll. Cardiol. 68, 1195-1205 (2016).
56. Barbanti, M. et al. Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement. Circulation 128, 244-253 (2013).
57. Roy, D. A. et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J. Am. Coll. Cardiol. 61, 1577-1584 (2013).
58. Testa, L. et al. CoreValve implantation for severe aortic regurgitation: A multicentre registry. EuroIntervention 10, 739-745 (2014).
59. Seiffert, M. et al. Initial german experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. JACC Cardiovasc. Interv. 7, 1168-1174 (2014).
60. Wendt, D. et al. Transapical transcatheter aortic valve for severe aortic regurgitation: expanding the limits. JACC Cardiovasc. Interv. 7, 1159-1167 (2014).
61. Urena, M. et al. Transcatheter aortic valve replacement to treat pure aortic regurgitation on noncalcified native valves. J. Am. Coll. Cardiol. 68, 1705-1706 (2016).
62. Dvir, D. et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 312, 162-170 (2014).
63. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02207569 (2016).
64. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02202434 (2017).